Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1152


Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells.

Uchino M, Kojima H, Wada K, Imada M, Onoda F, Satofuka H, Utsugi T, Murakami Y.

BMC Cancer. 2010 Aug 10;10:414. doi: 10.1186/1471-2407-10-414.


SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.

Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr, Badve S, Srour EF, Nakshatri H.

BMC Cancer. 2010 Aug 6;10:411. doi: 10.1186/1471-2407-10-411.


[Detection of breast cancer stem cells and the expression of key molecules in Hedgehog signaling pathway].

Lu ZH, Jia J, Ren J, Ma B, DI LJ, Song GH.

Beijing Da Xue Xue Bao. 2008 Oct 18;40(5):480-5. Chinese.


Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.

Leth-Larsen R, Terp MG, Christensen AG, Elias D, Kühlwein T, Jensen ON, Petersen OW, Ditzel HJ.

Mol Med. 2012 Sep 25;18:1109-21. doi: 10.2119/molmed.2012.00091.


CD24 enhances DNA damage-induced apoptosis by modulating NF-κB signaling in CD44-expressing breast cancer cells.

Ju JH, Jang K, Lee KM, Kim M, Kim J, Yi JY, Noh DY, Shin I.

Carcinogenesis. 2011 Oct;32(10):1474-83. doi: 10.1093/carcin/bgr173.


CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion.

Cho SH, Park YS, Kim HJ, Kim CH, Lim SW, Huh JW, Lee JH, Kim HR.

Int J Oncol. 2012 Jul;41(1):211-8. doi: 10.3892/ijo.2012.1453.


Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.

Ziegler E, Hansen MT, Haase M, Emons G, Gründker C.

Breast Cancer Res Treat. 2014 Nov;148(2):269-77. doi: 10.1007/s10549-014-3159-4. Erratum in: Breast Cancer Res Treat. 2016 Feb;156(1):209-10.


Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes.

Leccia F, Nardone A, Corvigno S, Vecchio LD, De Placido S, Salvatore F, Veneziani BM.

Cytometry A. 2012 Nov;81(11):960-72. doi: 10.1002/cyto.a.22095.


Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.

Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV.

J Natl Cancer Inst. 2010 Nov 3;102(21):1637-52. doi: 10.1093/jnci/djq361.


CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.

Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, Birnbaum D, Bertucci F, Chabannon C.

Breast Cancer Res. 2009;11(1):R1. doi: 10.1186/bcr2215.


The role of a new CD44st in increasing the invasion capability of the human breast cancer cell line MCF-7.

Fang XJ, Jiang H, Zhao XP, Jiang WM.

BMC Cancer. 2011 Jul 12;11:290. doi: 10.1186/1471-2407-11-290.


Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells.

Bambang IF, Xu S, Zhou J, Salto-Tellez M, Sethi SK, Zhang D.

Lab Invest. 2009 Nov;89(11):1229-42. doi: 10.1038/labinvest.2009.87.


Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).

Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA.

Biochem Biophys Res Commun. 2010 Jun 18;397(1):27-33. doi: 10.1016/j.bbrc.2010.05.041.


Fascin, an actin-bundling protein, promotes breast cancer progression in vitro.

Xing P, Li JG, Jin F, Zhao TT, Liu Q, Dong HT, Wei XL.

Cell Biochem Funct. 2011 Jun;29(4):303-10. doi: 10.1002/cbf.1750.


Tumor associated macrophage × cancer cell hybrids may acquire cancer stem cell properties in breast cancer.

Ding J, Jin W, Chen C, Shao Z, Wu J.

PLoS One. 2012;7(7):e41942. doi: 10.1371/journal.pone.0041942.


CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.

Lü X, Xu K, Lü H, Yin Y, Ma C, Liu Y, Li H, Suo Z.

Ultrastruct Pathol. 2011 Apr;35(2):72-8. doi: 10.3109/01913123.2010.544843.


MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.

Gwak JM, Kim HJ, Kim EJ, Chung YR, Yun S, Seo AN, Lee HJ, Park SY.

Breast Cancer Res Treat. 2014 Aug;147(1):39-49. doi: 10.1007/s10549-014-3069-5.


CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties.

Sun H, Jia J, Wang X, Ma B, Di L, Song G, Ren J.

Clin Transl Oncol. 2013 Jan;15(1):46-54. doi: 10.1007/s12094-012-0891-2.

Items per page

Supplemental Content

Support Center